Mon, Jul 14, 2014, 6:48 AM EDT - U.S. Markets open in 2 hrs 42 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Sep 11, 2011 3:20 PM Flag

    Phase 1 MTC data review: question , Pt 1

    I grabbed the following from the 7/6/11 EXEL Cabo update. This is the same news release that announced the 3 month delay of MTC P3 results...

    "The phase 1 trial enrolled a total of 37 patients with 35 patients being response evaluable. It showed a 29% rate of confirmed partial responses. These responses were generally durable with a response duration of up to 48+
    months per the most recent update. Four patients are in continued response at the
    current time. Additionally, 15 patients (41%)
    had stable disease lasting longer than 6
    months with some patients continuing on study
    3+ years after study initiation. Activity was
    independent of both RET mutation status and
    prior treatment with tyrosine kinase inhibitors,
    including vandetanib."

    I find the last sentence both compelling and intriguiging. Does the specific inclusion of comparison to Vandetinib suggest that Cabo is a better therapeutic agent, or simply that it has shown to favorably react where Vandetinib has not?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ...later treated w/ CABO. Activity noted. Interesting, no?
      My conjecture is that either the AE was too stressful...or the vandetanib less than effective... Is it a sound inference to suggest that-for some patients-CABO may prove to be a best,if only more effective choice.
      Conversely, I have been looking for a former CABO recipient...currently treated w/ vandetanib. I can find no evidence of this...
      Anyone...?

 
EXEL
3.325+0.780(+24.00%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.